Introduction
Nodal staging constitutes an element of great importance in the treatment planning for patients with early breast cancer. Sentinel lymph node (SLN) biopsy (SLNB) is the standard practice for patients with clinically negative axillary evaluation due to its high identification rate and high negative predictive value [1] . In 2010, the ACOSOG Z0011 trial [2] demonstrated in a highly selected group of patients with only 1 or 2 positive SLN that SLNB alone resulted in rates of local control, disease-free survival, and overall survival equivalent to those seen after axillary lymph node dissection (ALND), but with significantly lower morbidity. Although the National Comprehensive Cancer Network recommends considering no further surgery beyond SLNB for patients meeting ACO-SOG Z0011 eligibility criteria according to those results, in Argentina standard practice still includes ALND when macrometastasis is detected in the SLN. The ACOSOG Z0011 trial included women with T1-2 tumors treated with breast conserving surgery (BCS) and with 1 or 2 positive SLN, presuming a low-risk population. In consequence, applying these criteria to the general population of women with breast cancer must be done with caution and may need more evaluation [3] [4] [5] .
Accurate prediction of non-SLN positivity may help to select patients benefiting from being spared ALND; however, the ACO-SOG Z0011 results have raised doubts as to its value as no effect on survival was observed. Several studies have proposed clinical and pathologic factors (tumor size, number of positive SLN, and age) as predictive factors for more extensive axillary involvement [6] [7] [8] [9] [10] [11] [12] . Nevertheless, quality data is still missing in order to propose possible practice changes.
The purpose of this study was to determine the rate of breast cancer patients that fulfilled the ACOSOG Z0011 criteria and clini-
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Patients and Methods
A retrospective analysis of the Breast Cancer Registry ('Registro de Cáncer de Mama', RCM) of the Argentinian Society of Mastology was carried out. This electronic database was initiated in 2010 and includes the collaboration of public and private centers of different Argentinean cities including Buenos Aires, La Plata, Cordoba, and Tucuman. The ethnic background of Argentina's population is Caucasian in its majority.
All patients included in the RCM database gave signed informed consent before surgery allowing to share their data.
Inclusion and Exclusion Criteria
Patients' fulfillment of ACOSOG Z0011 was defined by the following inclusion criteria: women aged 18 or more, with histologically confirmed invasive breast carcinoma clinically measuring 5 cm or less, no palpable adenopathies, treated with lumpectomy with negative margins, and SLN labelled with technetium and blue dye with metastasis documented by frozen section, touch preparation, or hematoxylin-eosin staining on formalin-fixed paraffin-embedded samples. All patients received whole breast external beam radiotherapy. Patients were excluded if they had 3 or more positive SLN, matted nodes, or gross extranodal disease, or if they had received neoadjuvant endocrine therapy or chemotherapy.
Statistical Analysis
Categorical variables were expressed as absolute numbers and percentages. Continuous variables were described in terms of means and standard deviations if normally distributed, or medians and interquartile ranges (IQR) otherwise. Comparisons between groups were conducted using the Student t-test and the Wilcoxon rank sum test for continuous variables, and the chi-square test and Fisher's exact test for categorical variables. The relationships between each of the variables and non-SLN involvement were assessed individually using univariate analysis. The variables that were assessed as statistically significant in univariate analysis were included in multivariate analysis. Multivariate logistic regression was used to determine factors predictive of non-SLN involvement. A p value of <0.05 was considered statistically significant. Statistical analysis was carried out with Stata 11 (StataCorp, College Station, TX, USA).
Results
The database included 8,262 patients with breast cancer stage I-III. Of the patients with surgical axillary procedures, 51.89% (n = 4,287) had an SLN evaluation of which 22.7% (n = 973) where positive. Following the criteria of ACOSOG Z0011, 348 patients were included . The clinical characteristics of this group are described in table 1 .
Patients had a median of 2 (IQR 1-2) SLN resected and a median of 1 (IQR 1-1) positive SLN. 47 (13.51%) patients had micrometastasis in the SLN. Patients with positive SLN underwent ALND with a median of 12 (IQR 10-16) non-SLN resected. When further ALND was carried out, 52.3% (n = 182) had metastatic disease in non-SLN.
Univariate Analysis of Factors Associated with Non-SLN Positivity
Clinical and pathologic variables were analyzed in order to determine its possible association with residual axillary metastatic disease after SLN dissection. Results are shown in table 2 .
Histological grade, tumor size, age older than 50 years, and postmenopausal status showed significant association with non-SLN positivity. As can be seen in figure 1 A, histological grade shows clear differences between patients with and those without metastasis in lymph nodes other than SLN. In the subgroup of patients with G3 tumors, 64.81% had non-SLN with metastasis compared to 47.42% in the subgroup with G1-2 tumors (p = 0.004). Consistently, among patients with metastasis only 4.54% were grade 1 versus 21.61% among those without other lymph nodes involved. Considering tumor size, figure 1 B shows that 69.67% of patients with T2 tumors had positive non-SLN while only 47.09% of T1 patients presented with positive non-SLN (p < 0.001). Likewise, when analyzing the proportion of T2 tumors in the groups with positive versus negative non-SLN, evident disparity was observed (46.7 vs. 25.34%).
Figure 1 C presents the relationship between age and non-SLN positivity. Patients older than 50 years revealed positive non-SLN in 61.27%, while only 45.97% of the subjects aged ≤ 50 years had positive non-SLN (p = 0.007). Also, the proportion of older patients significantly differed between patients with positive versus negative non-SLN (68.68 vs. 54.11%).
Due to the direct correlation between age and postmenopausal status (95.5% of patients older than 50 years were postmenopausal), we decided to include in the logistic regression model only 3 variables: histological grade, tumor size, and age. The results of the multivariate analysis are shown in table 3 and show that for each patient without these characteristics that have positive non-SLN, 2 patients with these variables present with positive non-SLN (OR 1.81, 2.39, and 1.95, respectively).
Discussion
Currently, it is widely accepted that ALND does not improve survival in patients with negative SLN or micrometastatic disease [13, 14] . ACOSOG Z0011 presented practice-changing results that need to be carefully analyzed. The trial included a highly selected group of patients with T1-2 tumors, treated with BCS and SLNB with resulting positivity in less than 3 nodes. This was a low-risk population that received adjuvant treatment (radiotherapy ± chemotherapy ± endocrine therapy) aimed at controlling eventual persistence of axillary metastasis. However, some confusion has been generated, pertaining to the application of these findings without satisfying the strict trial criteria. Publications related to the changes generated by these results in countries like Spain include patients with mastectomy and SLN positivity not receiving ALND in 10.96% [15] . Adequate analyses have shown that in European centers less than 10% of patients could benefit from this practice [5, 16] , equating to 8.12% of the patients with SLN detection in our analysis. However, this population comprises 35% of the patients with positive SLN biopsy, making them candidates for avoiding ALND. Our study also provides information on the degree to which the ACOSOG Z0011 population is representative of patients undergoing primary BCS for clinical T1/T2 node-negative breast cancers. In our patient cohort, after refining its characteristics according to the inclusion and exclusion criteria, patient and tumor characteristics were similar to those of the women enrolled in ACOSOG Z0011. Similarities exist for age (55 vs. 55 years), proportion of T2 (36 vs. 31%), hormone receptor negativity (15 vs. 16%), and lymphovascular invasion (45 vs. 40%). Important differences can be seen in the rate of micrometastatic disease in the SLN and the rate of non-SLN positivity. In our population, the latter was 52.3%, while it was only 27% in ACOSOG Z0011 patients and 33% in the AMAROS trial [17] . Our results are similar to those reported by several authors for European [18] and Argentinian cohorts [19, 20] ranging from 44 to 59%, and a 2006 meta-analysis including more than 8,000 patients described a positivity rate of 53% [21] . We understand that the difference compared to these 2 important trials resides in the great variation in micrometastatic disease, as our cohort presented with only 13.5% (n = 47) of positive SLN due to micrometastasis compared to 37.5% (n = 137) in ACOSOG and 29% (n = 215) in AMAROS.
Patients with more aggressive tumor phenotypes such as estrogen receptor-negative or HER2-positive tumors were not more likely to have extensive nodal disease. This supports previous evidence from different studies in which patients with these tumor types did not show differences in axillary cancer burden although presenting a greater risk of recurrence and poor prognosis [22, 23] . Therefore, these patients should not be excluded from being given the option of avoiding ALND.
Positivity of non-SLN is the accepted risk when deciding not to pursue ALND in the case of metastatic SLN. As has been stated before, the percentage of patients with residual disease is variable depending on the cohort described. Hence, promoting this practice as a standard requires an exhaustive evaluation in order to adequately select those patients who are suitable candidates and will benefit from avoiding further surgery without affecting long-term prognosis. Evidence from past studies has demonstrated that certain clinical or pathological characteristics of breast tumors increase the risk of nodal involvement. Series agree in terms of tumor size, histological grade, lymphovascular invasion, number of SLN resected, macrometastatic nodal disease, and extracapsular extension as predictive factors [6] [7] [8] [9] [10] [11] [12] . Furthermore, some of these analyses have proposed and developed the use of nomograms to estimate the risk of metastatic disease in axillary nodes in order to define if ALND is needed [24, 25] .
The application of this less invasive approach to axillary management involves the understanding that low-volume residual disease in the axilla will be treated with tangent field irradiation and systemic therapy. This concept is based on the evidence generated by 2 important scenarios: i) recurrence rate in patients with radiotherapy and endocrine therapy having no axillary surgery [26] [27] [28] and ii) axillary complete response rate in neoadjuvant treatment [29] . Trials on avoiding ALND such as ACOSOG Z0011 or IBCSG 23-01 suggest that regional recurrence is low even in patients with untreated additional nodal metastasis (13-27%) [2, 30] .
Our database analysis is the first in Argentina to specifically assess patients according to ACOSOG Z0011 criteria. It has shown that patients older than 50 years with T2 or histological grade 3 tumors have a 2-fold risk of nodal disease being left untreated if ALND is avoided. This analysis has important limitations as it is based on retrospective data from a national database, which may favor certain errors and mislead data interpretation. Consequently, prognostic relevance is missing, but our results support the understanding of the situation and epidemiology in Latin-American countries. Argentina as many of its neighbors does not have adequate screening programs, and diagnosis and treatment may vary compared to developed countries. Thoroughly understanding our population may allow us to tailor therapy and make optimal decisions similar to the practice in developed countries. Survival results of ACOSOG Z0011 with 10-year follow-up have proven that prognosis is not affected by the decision for or against ALND [31] ; however, patients presenting with T2 or histological grade 3 tumors were scarcely represented.
